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A major barrier to research on Parkinson’s disease is inaccessibility of diseased tissue for study. 
one solution is to derive induced pluripotent stem cells from patients and differentiate them 
into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully 
penetrant, aggressive form of Parkinson’s disease with dementia. α-synuclein dysfunction is 
the critical pathogenic event in Parkinson’s disease, multiple system atrophy and dementia 
with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA 
triplication patient and an unaffected first-degree relative. When these cells are differentiated 
into midbrain dopaminergic neurons, those from the patient produce double the amount of   
α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause 
of Parkinson’s disease in these individuals. This model represents a new experimental system 
to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic 
basis of neurodegeneration caused by α-synuclein dysfunction. 
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P
arkinson’s disease (PD) is the most common neurodegenera-
tive movement disorder1. The pathological hallmark is loss 
of midbrain dopaminergic neurons in the substantia nigra 
pars compacta, and abnormal fibrillar cytoplasmic inclusions called 
Lewy bodies are typically deposited in surviving neurons through-
out the brain2. It is unclear why neurons degenerate in PD, but clues 
have been provided through studying the underlying genetics of the 
disorder3. SNCA, encoding α-synuclein, was the first gene linked 
to familial PD4, and α-synuclein is the principal protein constitu-
ent of Lewy bodies5. Furthermore, multiplications of the SNCA gene 
cause familial PD, with several duplication and triplication kindreds 
described6,7. Finally, multiple genome-wide association studies have 
established that variation at the SNCA locus is the most significant 
genetic risk factor for sporadic PD8,9. A meta-analysis of this data 
has found further association 5′ of SNCA, suggesting variation in 
promoter/enhancer regions may modulate expression of SNCA10.
Taken  together,  α-synuclein  clearly  has  a  central  role  in  PD 
pathogenesis, but modelling how it leads to neuronal death in PD 
has been difficult, in part, owing to the inaccessibility of diseased 
neurons from patients. Moreover, by the time PD manifests clini-
cally, most of these cells have already been lost11. Transgenic models 
of α-synuclein have illuminated pathogenic processes operating in 
PD12,13, but have not fully replicated the phenotype of the human 
disease14. Existing primary and tumour cell models also have major 
drawbacks. Primary neuronal cultures from mice or rats are difficult 
to maintain in vitro and do not self-renew, and wild-type animals 
have an amino acid at position 53 of α-synuclein that, in humans, 
causes PD15. Transformed cell lines can be genetically manipulated 
for studying proteins of interest, but these cells carry mutations in 
genes involved in apoptosis and chromosomal rearrangements that 
can disrupt cell signalling pathways, and are phenotypically differ-
ent from the cells affected by PD, all of which limits their use as 
a model system16,17. Many of the existing cellular models rely on 
poorly controlled overexpression of transgenes, a particular draw-
back  when  modelling  a  disease  where  subtle  alteration  of  gene   
dosage is critical18.
A potential solution is to utilize reprogamming technology to 
generate disease-specific induced pluripotent stem cells (iPSCs)19. 
iPSCs derived from patients with PD can then be differentiated to 
midbrain dopaminergic neurons for disease modelling. Generation 
of iPSCs from individuals with sporadic PD has been reported20,21. 
Given the long latency and variability of disease progression, and 
that epigenetic modifications are erased during the process of gen-
erating iPSCs, it is unclear whether such patient-derived cells can 
recapitulate pathogenesis in cell culture22,23. More recently, an iPSC 
model of PD caused by homozygous G2019S mutation of LRRK2 
has been reported24. However, LRRK2 mutations have incomplete 
penetrance, even when homozygous25.
To overcome these difficulties, we sought to develop an iPSC-
based model of PD with fibroblasts from an affected member of the 
Iowa kindred carrying a triplication of the SNCA locus, to serve as 
a model of the sporadic disorder. SNCA triplication results in four 
copies of the SNCA gene and a doubling of messenger RNA and 
protein  expression6,26,27.  This  causes  early  onset,  rapidly  progres-
sive form of PD that is fully penetrant, circumventing the influ-
ence of epigenetic changes, and maximizing the chances of an iPSC 
model developing a disease phenotype in vitro. We asked whether it 
would be possible to recapitulate α-synuclein doubling in patient-
derived iPSCs differentiated into dopaminergic neurons. If so, the 
α-synuclein doubling would have the important benefit of provid-
ing a measurable biomarker, which could be used as a diagnostic 
test to validate the model, and provide a platform for drug screen-
ing and mechanistic experiments. We describe the generation of 
sets of iPSC lines from a patient with triplication of SNCA, and an 
unaffected first-degree relative, serving as a control with a similar 
genetic background, to minimize phenotypic differences not due 
to the triplication. Once differentiated into cultures enriched for 
midbrain dopaminergic neurons, a twofold increase in expression 
of SNCA was demonstrated in patient-derived cells, when com-
pared with control cells that had undergone neural differentiation 
with equivalent efficiency. A major source of variability identified 
in this work was iPSC clonal variation, which partly contributed to 
differences in efficiency of differentiation. This emphasizes the need 
to generate multiple iPSC lines from each individual involved in a 
study of this nature, to identify clones with capacity to differentiate 
into cells of interest, and also to take steps to compare neuronal   
cultures with equivalent differentiation efficiency.
Results
PD  fibroblasts  do  not  express  α-synuclein.  Muenter  and  co-
workers reported the original description of the Iowan kindred, with 
a long family history of early-onset Parkinsonism and dementia28. 
Subsequently, a triplication of a region on Chr4q22 encompassing 
the SNCA locus was identified in this kindred6. Fibroblast cultures 
were  established  from  dermal  biopsies  provided  by  a  female 
member with PD and an unaffected first-degree relative. For clinical 
description and video documentation of the patient, see case 9-60 
in Gwinn et al.29 We refer to patient-derived cells as AST (alpha-
synuclein triplication) and relative-derived cells as NAS (normal 
alpha-synuclein).  Neither  AST  nor  NAS  fibroblasts  expressed 
detectable levels of α-synuclein protein (Fig. 1a). This suggests that 
the triplication does not result in significant ectopic expression of 
this pre-synaptic protein.
iPSC generation and characterization. To generate iPSCs, fibrob-
lasts were virally transduced with four reprogramming factors19. 
Figure 1b depicts fibroblasts and primary iPSC colonies at day 20 
post-viral transduction. A total of 30 AST and 10 NAS iPSC lines 
were established. Cell lines with the strongest retroviral silencing 
have been shown to differentiate more efficiently and is indicative 
of complete reprogramming30. Therefore, all lines were examined 
for transgene silencing relative to fibroblasts 3 days post-viral trans-
duction (acting as a positive control). The cell lines with the lowest 
levels of transgene expression were chosen for further analysis (Fig. 
1c). All chosen iPSC lines exhibited good hESC colony morphology 
and growth characteristics, and have been passaged more than 35 
times, with more than 6 months in continual culture.
Colonies from NAS and AST iPSC lines demonstrated robust 
expression of the pluripotency markers OCT4, SSEA4, TRA-1-81 
and NANOG (Fig. 1d, e). Endogenous expression of the pluripo-
tency genes OCT4, SOX2, NANOG and REX1 was reactivated in 
all iPSC lines examined (Fig. 1f). The OCT4 and SOX2 primers 
do not recognize the mouse Oct4 and Sox2 transgenes used to 
reprogram the cells. No significant differences between AST and 
NAS iPSC lines were observed with respect to expression of key 
pluripotency genes.
Triplication status and chromosomal integrity. SNCA gene dosage 
was re-examined in the AST iPSC lines to confirm they retained the 
triplication: genomic qPCR for SNCA exons 1 and 4 confirmed that 
AST iPSC lines had twice as many SNCA alleles as NAS iPSC lines 
(Fig. 2a). Genomic DNA samples from the two participants, the two 
fibroblast lines, four iPSC lines, and differentiated neurons were fur-
ther analysed on genome-wide SNP arrays. This analysis confirmed 
that those samples derived from the unaffected relative were normal 
at Chr4q22 (Fig. 2b) whereas the triplicated region was retained 
intact in all samples derived from the patient (Fig. 2c). We were able 
to refine the triplication region further6 and determined the size to 
be 1.505 Mb (Fig. 2d). We were also able to survey the rest of the 
genome for chromosomal integrity in these cell lines. Two PD iPSC 
lines (AST13 and AST18) and one control iPSC line (NAS2) did not 
acquire any chromosomal aberrations after more than 25 passages. ARTICLE     
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However one control iPSC line, NAS9, contained a duplication of a 
large part of chromosome 5q, an extended run of homozygosity in 
chromosome 12q, and a small deletion at the end of chromosome 
4q (Fig. 2e). Chromosomal abnormalities of this nature are consist-
ent with published reports of iPSCs where this has been specifically 
examined31. However, such analysis has not been reported in the 
iPSC disease models published so far. This SNP data also confirmed 
that AST and NAS iPSCs and neurons were indeed derived from the 
PD patient and unaffected relative, respectively (Table 1)32.
Directed  differentiation  to  dopaminergic  neurons.  We  used  a 
feeder-free monolayer culture method of inducing neural differen-
tiation under defined conditions, via dual inhibition of SMAD sig-
nalling33. This approach combines Noggin (an inhibitor of BMP4) 
and SB431542 (an inhibitor of Lefty/Activin/TGFβ pathways) to 
achieve robust neural differentiation. Here we have also added Dor-
somorphin (a chemical BMP inhibitor) as a partial substitute for 
Noggin, to improve efficiency and reduce costs34. The dual SMAD 
inhibition protocol has been employed to generate floor plate tissue 
from human ESCs35. Fasano and co-workers demonstrated directed 
differentiation  of  human  ESCs  into  floor  plate  tissue  via  initial 
dual SMAD inhibition in conjunction with early high-dose sonic 
hedgehog (SHH) signalling35. We commenced neural differentia-
tion with dual SMAD inhibition for 1 day, followed by SHH, WNT1 
and Dkk1 blocking antibody treatment. After 9 days of floor plate   
differentiation, the protocol was switched to promote maturation of 
midbrain dopaminergic neurons from neural progenitors derived 
from human ESCs (Fig. 3a)36.
Eight AST and six NAS iPSC lines were subjected to the floor 
plate-dopaminergic differentiation protocol. Five AST lines and four 
NAS lines produced viable neurons that could be analysed. After 20 
to 31 days, differentiated iPSCs were examined for tyrosine hydroxy-
lase (TH - the rate-limiting enzyme in the biosynthetic pathway to 
dopamine, used as a marker of dopaminergic neuronal identity) 
and neuron-specific class III β-tubulin (TuJ1 - used as a marker of 
pan-neuronal identity) and all showed robust expression of these 
markers (Fig. 3b). We performed blind cell counts on micrographs 
fluorescently labelled for TH and TuJ1, and found that AST iPSCs 
yielded 37% (s.d. 5) TH-positive cells as a proportion of TuJ1-posi-
tive cells whereas NAS iPSCs yielded 28% (s.d. 4), which is not sig-
nificantly different (Fig. 3c). We confirmed the midbrain identity 
of these TH-positive neurons by co-immunolabelling with the ven-
tral midbrain marker LMX1B (Fig. 3d)37. To further confirm their 
midbrain dopaminergic identity, we performed expression analysis 
of LMX1A, NURR1, TH and DAT (Fig. 3e). We observed a range 
of expression of these factors that was not linked to genotype. This 
may reflect clonal variation or efficiency of neuralization that has 
been previously observed in iPSCs38. Genome-wide SNP analysis of 
AST iPSC-derived neuronal cultures confirmed that the triplication 
region had remained intact during differentiation (Fig. 3f).
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Figure 1 | Multiple iPSC lines derived from a PD patient with SNCA triplication and an unaffected relative exhibit hallmarks of pluripotency.  
(a) Western blot analysis of AsT and nAs fibroblasts confirms a lack of α-synuclein protein. Lysate of sH-sY5Y neuroblastoma cells transfected with an 
α-synuclein expressing plasmid was used as a positive control, and β-actin as a loading control. (b) Phase contrast images of AsT and nAs fibroblasts  
and de novo iPsC colonies on snL feeder cells at day 20 post-viral transduction. scale bar, 100 µm. (c) Quantitative RT–PCR for retroviral transgene 
expression of the four reprogramming factors (Oct4, Sox2, c-Myc, Klf4). Expression in iPsC lines was normalized to transgene expression of nAs  
fibroblasts 3 days post-viral transduction (nAs VT). Also shown are negative controls: untransduced fibroblasts (nAs fibs) and human EsCs (shef4 
hEsC). (d, e) Representative iPsC colonies derived from nAs fibroblasts (d) and AsT fibroblasts (e) stained positive for the pluripotency markers oCT4, 
ssEA4, TRA-1-81 and nAnoG. scale bar, 100 µm. (f) Endogenous expression of OCT4, SOX2, NANOG and REX1 in two AsT and two nAs iPsC lines, 
normalized to expression in human EsCs (shef4), found a similar expression profile in all lines examined. Expression of these genes was absent in human 
fibroblasts (not shown). Error bars represent standard deviation of technical replicates, n = 3.ARTICLE
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α-Synuclein protein could be detected in all iPSC-derived neu-
ronal cultures (Fig. 4a, b). We observed considerable heterogeneity 
of  expression  of  α-synuclein  that  may  reflect  different  neuronal 
subtypes or different stages of neuronal maturity39. However, α-
synuclein was found to be expressed in all TuJ1 +  cells. In contrast, 
it  was  not  detectable  in  fibroblasts  by  immunocytochemistry  or   
western (Fig. 1a).
Triplication  gene  set  is  over-expressed  in  AST  neurons.  Gene 
expression profiling was carried out on the AST and NAS fibrob-
lasts, four iPSC lines (AST13, AST18, NAS2, and NAS9) and eight 
neuronal cultures (Day 23 and Day 31 of the 4 iPSC lines). Prin-
cipal component analysis (PCA) and hierarchical clustering found 
that the three groups of cell samples clustered separately, with the 
iPSCs most closely associated with a control human ESC line, Shef4   
(Fig. 5a, b). Scatter plots comparing gene expression of iPSCs, and 
fibroblasts with that of human ESCs found that the overall expression 
profiles of human ESCs was more similar to iPSCs than the fibroblast 
cell lines (Fig. 5c). We were unable to detect any significant differ-
ences (at false discovery rate of 0.05) in genome-wide gene expres-
sion between human ESCs and iPSCs or NAS iPSCs as compared 
with AST iPSCs. To further confirm that our iPSC lines exhibited 
a pluripotent expression profile, we compared global gene expres-
sion with all publicly available hESC gene expression data sets using 
the same platform. The resulting PCA plots demonstrate that the 
expression profiles of the iPSC lines described are indistinguishable   
from established hESC lines (Fig. 5d). Following the creation of 
a triplication gene set (defined as all genes within the triplication 
region, shown in Fig. 2d), we used gene set enrichment analysis 
(GSEA) to demonstrate a highly significant enrichment (nominal 
P-value  < 0.0001) of this set within AST as compared with NAS 
neurons (Fig. 5e). Although we were also able to demonstrate sig-
nificant  enrichment  (nominal  P-value   < 0.05)  of  the  triplication 
gene set in AST versus NAS iPSCs, no significant enrichment could 
be detected in AST versus NAS fibroblasts (nominal P-value = 0.09). 
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Figure 2 | Triplication region is maintained in patient-derived fibroblasts and iPSCs. (a) Quantitative genomic PCR for SNCA exons 1 and 4 
demonstrates doubling of gene dosage in patient-derived AsT iPsC lines when compared with nAs iPsC lines. Representative data shown. SNCA was 
normalized to β-globin (HBB) and β2-microglobulin (B2MG). (b) snP profiles of chromosome 4q22 in DnA from unaffected relative blood, fibroblasts 
and iPsCs demonstrates that this region is normal. (c) The same region analysed in DnA from patient blood, fibroblasts and iPsCs confirms that the 
triplication region is present and is retained during reprogramming. (d) The triplication region is defined as chr4:89,375,425 to 90,880,891, spanning the 
following genes: HERC5, PIGY, HERC3, NAP1L5, FAM13AOS, FAM13A, TIGD2, GPRIN3, SNCA and MMRN1. LOC644248 is also in the triplication region but not 
yet defined by Refseq. (e) Genome-wide snP analysis of nAs9 iPsCs identified the following chromosomal abnormalities: a small deletion at the end of 
Chr4q, a duplication of part of Chr5q and an extended run of homozygosity occupying most of Chr12q.
Table 1 | Pi-hat analysis confirms origin of iPSC lines and 
neurons.
Sample 1 Sample 2 Pi-hat
Blood DnA (AsT) AsT fibroblasts 0.9999
AsT fibroblasts AsT13 iPs cells 0.9998
AsT fibroblasts AsT18 iPs cells 0.9998
AsT18 iPsCs AsT18 neurons 0.9999
Blood DnA (nAs) nAs fibroblasts 0.9999
nAs fibroblasts nAs9 iPs cells 0.9797
nAs fibroblasts nAs2 iPs cells 0.9999
nAs2 iPsCs nAs2 neurons 0.9999
Blood DnA (AsT) Blood DnA (nAs) 0.5
Pi-hat is the estimated proportion of genes shared identical by descent at the marker locus. 
Identical=1, 50% shared genome-wide=0.5.ARTICLE     

nATuRE CommunICATIons | DoI: 10.1038/ncomms1453
nATuRE CommunICATIons | 2:440 | DoI: 10.1038/ncomms1453 | www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
We estimated the statistical significance (nominal P value) of the 
enrichment score by using an empirical gene set-based permutation 
test procedure, as described in Subramanian et al.40 Specifically, we 
observed that SNCA expression is elevated in AST compared with 
NAS iPSCs and was further increased when these cells were dif-
ferentiated into neurons (Fig. 5f). Expression was not detected in 
fibroblasts.
Assessment of neuralization and SNCA expression. To determine 
whether AST neurons recapitulate the elevated SNCA expression 
observed in postmortem brain tissue in patients from this kindred, 
and to confirm the microarray results (Fig. 5f), we performed fur-
ther neuronal differentiations and carried out quantitative RT–PCR 
analysis of SNCA. We found that AST-derived neurons expressed 
approximately double the quantity of SNCA mRNA as NAS-derived 
neurons, when controlling for efficiency of neuralization by nor-
malizing to the pan-neuronal marker MAPT (Fig. 6a). SNCA has 
two paralogous genes, SNCB and SNCG, which respectively encode 
β- and γ-synuclein. All have been found in neuritic pathology in PD 
and dementia with Lewy bodies41. Wild-type β-synuclein inhibits 
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Figure 3 | Patient and control iPSC lines differentiate efficiently into midbrain dopaminergic neurons. (a) schematic of the dual smAD inhibition/floor 
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( > 80%). A minority of TH +  cells are negative for LmX1B (arrowheads). scale bar, 100 µm. (e) Quantitative RT–PCR analysis for midbrain dopaminergic 
neural markers (LMX1A, NURR1, TH and DAT) in AsT and nAs neuronal cultures. To control for efficiency of neuralization we normalized expression to the 
pan-neuronal marker mAPT. Error bars represent standard deviation of technical replicates, n = 3. (f) snP analysis of AsT-derived neurons confirms that 
the triplication region is retained intact following neuronal differentiation.ARTICLE
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α-synuclein aggregation in vitro and limits pathology due to human 
α-synuclein expression in transgenic mice, but can cause neurode-
generation when mutated42,43. In contrast, transgenic overexpression   
of  wild-type  γ-synuclein  leads  to  neurodegeneration44.  Overall,   
β-synuclein appears to be protective whereas γ-synuclein may exert 
its own toxicity. We observed that SNCG expression was signifi-
cantly lower in AST neurons, suggesting a possible compensatory 
mechanism. No significant difference was observed in the expres-
sion of SNCB (Fig. 6a).
To further probe the possibility of clonal variation, we inves-
tigated the level of expression of SNCA in multiple NAS and AST 
iPSC lines. AST13, AST18, NAS2 and NAS9 gave robust yields of 
neurons on repeated trials of neuralization. To control for heteroge-
neity of neuronal differentiation, we normalized SNCA expression 
to pan-neuronal markers (MAPT and NCAM). As for the dopamin-
ergic markers (Fig. 3e), we observed some variation between lines, 
but we consistently found at least a doubling of SNCA expression 
in AST-derived neurons when compared with NAS-derived neu-
rons (Fig. 6b). We next examined the level of α-synuclein protein 
expression in a pair of iPSC lines that differentiated with similar 
efficiency, AST18 and NAS2. A twofold increase in α-synuclein 
protein expression was observed in AST18 (Fig. 6c), which agreed 
with the difference in mRNA expression. Finally, we asked whether 
AST-derived neurons might release more α-synuclein into cell cul-
ture media than NAS-derived neurons, as this protein is known 
to be secreted by cells in culture45. We analysed 48 h conditioned 
media from several AST and NAS neuronal cultures and found 
significantly more α-synuclein released into the media from AST 
neurons (Fig. 6d).
Discussion
iPSC technology has the potential to revolutionize our understand-
ing  of  PD,  because  it  provides  the  opportunity  to  generate  and 
study disease-affected cells directly from patients. This approach 
has already been used to generate cell models for several neuro-
logical  conditions:  amyotrophic  lateral  sclerosis,  sporadic  PD, 
spinal muscular atrophy and familial dysautonomia have all been 
described21,46–48.
Here we describe iPSC lines with triplication of SNCA (AST), 
and  lines  from  a  non-affected  first-degree  relative  (NAS).  Both 
sets of iPSC lines were screened for retroviral transgene silencing, 
pluripotent marker expression, and differentiation efficiency in a 
floor plate-dopaminergic neuronal specification protocol. All of the 
lines derived from the patient fibroblasts have the SNCA triplication 
intact, as determined by PCR on genomic DNA, and confirmed in 
a subset of lines with genome-wide SNP analysis. Subsets of iPSC 
lines from the patient and unaffected relative have been successfully 
differentiated into dopaminergic neurons. These lines passed all cri-
teria, and patient-derived neurons exhibited a doubling of SNCA 
mRNA expression and α-synuclein protein. We highlight a number 
of potential variables that must be considered when establishing 
an iPSC disease model. Variability between iPSC clones, variable 
responses to neural differentiation protocols, and heterogeneity of 
neural differentiation must all be taken into account when consid-
ering the validity and robustness of pluripotent cell lines used to 
model human diseases such as PD.
These sources of variation have also been observed in other iPSC 
models38,49,50.  Therefore  it  is  an  implicit  requirement  to  generate 
  several  independent  iPSC  lines  from  each  patient  involved  in 
a study of this nature, and to examine efficiency of neuralization 
for fair comparisons to be made51. As we expect each neuronally 
  differentiated  patient-derived  iPSC  clone  to  exhibit  a  doubling 
of  SNCA  expression,  ours  is  a  simple  and  stringent  system  for 
  examining the robustness of the iPSC disease-modelling paradigm.
The application of iPSC technology to modelling diseases such 
as PD, with long latency and involvement of epigenetic factors that 
could be erased during reprogramming, is challenging22. However, 
we  chose  a  fully  penetrant,  early  onset  and  rapidly  progressive 
familial PD to offset these two potential problems as far as possi-
ble. Application of extrinsic agents, to stimulate oxidative stress for 
example, could be used to help accelerate development of a phe-
notype52. This has recently been performed to investigate LRRK2 
mutant iPSCs24. PD iPSC models are systems in which the earliest 
pathogenic changes that lead to disease can be studied, rather than 
ones in which end-stage pathology of PD is observed. The triplicated 
SNCA iPSCs are well positioned for these studies due to the fully 
penetrant and early-onset phenotype in humans. This is important, 
because determining these earliest responses might provide a mech-
anism whereby the disease can be halted before it progresses, and, 
furthermore, those pathological changes that occur at later stages in 
the disease may be protective rather than toxic53.
iPSCs carrying the SNCA triplication will also provide a valu-
able tool to investigate cell-to-cell propagation of pathology, being 
primed to develop disease54. These cells will also be of value in stud-
ying other synucleinopathies in vitro. Clinically, SNCA triplication 
can generate the full spectrum of the synucleinopathies, includ-
ing  progressive  supranuclear  palsy,  multiple  system  atrophy  and 
dementia with Lewy bodies, as well as PD28. Pathologically, cases 
can include glial deposition of α-synuclein reminiscent of the glial 
cytoplasmic inclusions found in multiple system atrophy55. The dif-
ferentiation of AST and NAS lines towards an oligodendroglial fate 
may be informative about the cellular processes operating in this 
disorder56.
In conclusion, we have derived a collection of iPSC lines from a 
PD patient with triplication of the α-synuclein locus, and an unaf-
fected first-degree relative. This study demonstrates the potential 
α-Syn DAPI
DAPI
TuJ1
TuJ1 α-Syn
Figure 4 | Expression of α-synuclein in iPSC-derived neuronal cultures 
is heterogeneous. Expression of α-synuclein was observed in all TuJ1 +  
neurons derived from AsT (a) and nAs (b) iPsCs. The majority of cells 
expressed low levels of α-synuclein (filled arrowheads) whereas 3–7% of 
TuJ1 +  cells expressed a high level of protein (open arrowheads). scale bar, 
100 µm upper panels, 400 µm lower panels.ARTICLE     
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of human dopaminergic neurons in vitro as a model for studying 
Parkinson’s disease. It also highlights the inherent variation in iPSC 
clones, which makes the interpretation of these models challenging. 
However, this collection of disease and control iPSC lines will serve 
as an invaluable resource to study many of the unresolved questions 
in PD pathogenesis.
Methods
Fibroblast cultures. Dermal fibroblast cultures were isolated from a member 
of the Iowa kindred carrying a triplication of the SNCA locus and an unaffected 
member of the family without this mutation, following approval of the Royal 
Free research ethics committee, Royal Free Hospital, London, UK and informed 
consent from the husband of the patient (as next of kin) and the unaffected relative. 
Samples were designated anonymous identifiers following collection. Skin punch 
biopsies (forearm) were cultured in 5 cm2 sterile Petri dishes at 37°C in 5% CO2 in 
2 ml DMEM supplemented with 10% fetal bovine serum, penicillin (50 U ml − 1), 
and streptomycin (50 µg ml − 1) until fibroblasts were seen to migrate from the skin 
explants. Media volume was increased by 0.5 ml every 2 days. When plates were 
confluent, fibroblasts were lifted from dishes by trypsinizing with TrypLE (Invit-
rogen) and transferred to 10 cm2 dishes for culturing. The case fibroblast sample 
(cat no. ND27760) has been deposited at the Coriell Institute for Medical Research 
(http://www.coriell.org/) and is freely available for research purposes.
iPSC generation. The four mouse reprogramming factors inserted into the pMXs  
vector backbone were obtained from Addgene (pMXs-cMyc #13375, pMXs-Klf4 
#13370, pMXs-Oct4 #13366, pMXs-Sox2 #13367)19. These were transfected into  
Platinum-A cells (Cell Biolabs #RV-102) with Lipofectamine 2000 (Invitrogen) to 
package viral particles. Target fibroblasts (100,000 cells) were transduced with virus in 
the presence of 6 ng ml − 1 polybrene (Millipore #Tr-1003-G) twice on consecutive days, 
then lifted with Accutase (Invitrogen) a day later and replated on irradiated SNL feeders 
(available from European Collection of Cell Cultures, ECACC). The day after replating, 
media was switched to hESC medium (KO-DMEM, 20% KSR, 2 mM l-glutamine,  
1× non-essential amino acids, 50 µM 2-mercaptoethanol, 50 U ml − 1 penicillin,  
50 µg ml − 1 streptomycin (all from Invitrogen), and 20 ng ml − 1 FGF2 (Peprotech))  
containing 0.5 mM valproate (Merck)57. Colonies were mechanically picked after  
~20 days and maintained on SNL feeders in hESC medium without valproate. Estab-
lished iPSC lines were maintained in hESC medium containing 10 ng ml − 1 FGF2.
Transgene silencing and marker gene expression. RNA was obtained from 
separate iPSC lines using the RNeasy Plus kit (Qiagen) according to manufacturer’s 
instructions. Complementary DNA was generated via Superscript III (Invitrogen), 
and qPCR reactions were carried out with SYBR Green (Qiagen) on a Lightcycler 
480 (Roche), with primer pairs specific to mouse Oct4, Sox2, Klf4 and c-Myc. 
Results were normalized to human TBP using the comparative C(T) method58 and 
compared with equivalent values determined from fibroblasts 3 days post-viral 
transduction (positive control), Shef4 human ES cells (negative control) and 
non-transduced human fibroblasts (negative control). cDNA was generated from 
neuralized iPSCs by the same method, and qPCR reactions were carried out with 
the Universal Probe Library system (Roche) and normalized to GAPDH or MAPT. 
All primers are described in Supplementary Table S1.
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde at room tem-
perature, or 100% methanol at  − 20°C for 15 minutes, then blocked and permea-
bilized with blocking buffer (2% goat serum, 0.1% Triton-X in phosphate buffered 
saline) overnight at 4°C before probing with the following primary antibodies 
(overnight in goat blocking buffer at 4°C): OCT4 (Santa Cruz #5279, mouse IgG2b, 
1:200), TRA 1-81 (Biolegend #330701, mouse IgMκ, 1:600), SSEA4 (DSHB, mouse 
IgG3κ, neat), NANOG (Abcam #ab21624, rabbit IgG, 1:1000), TuJ-1 (R&D systems 
#MAB1195, mouse IgG2A), TH (R&D systems #MAB1423 clone TH-2, mouse 
IgG1), LMX1B (Rabbit polyclonal from Dai et al.37, 1:2000) and α-synuclein (BD 
Transduction Laboratories #610787, mouse IgG1). Appropriate AlexaFluor-488 
and AlexaFluor-596-labelled secondary antibodies (Molecular Probes) were used 
at 1:1000, along with DAPI counterstaining, before imaging with an Olympus IX51 
inverted fluorescent microscope or Leica DM IRE2 confocal microscope.
SNCA triplication screening. Genomic DNA was obtained from individual cell 
lines using the DNA blood and tissue kit (Qiagen) according to manufacturer’s 
instructions, including RNase A to remove contaminating RNA. Dosage of SNCA 
was then assessed with SYBR Green qPCR on a Rotorgene unit (Qiagen) using 
primers specific for exons 1 and 4 of SNCA and β2-microglobulin (B2MG) and 
β-globin (HBB) as diploid control genes (Supplementary Table S1)59.
Monolayer neuronal differentiation. iPSC cultures were dissociated with Ac-
cutase (Invitrogen) to generate single-cell suspensions, then differentially plated 
on gelatin-coated plasticware for 1 h in hESC medium in the presence of ROCK 
inhibitor (Y27632, Ascent) to remove SNL feeders. The nonattached cells were 
resuspended in MEF-CM (R&D systems) with 10 ng ml − 1 FGF2 (Peprotech) and 
plated on growth-factor reduced Matrigel (BD) at a density of 25,000 cells cm − 2 
and allowed to propagate in self-renewal conditions for 72 h or until 70–90% 
confluent, whereupon media was changed to KSR medium containing 50 ng ml − 1 
Noggin (Peprotech), 10 µM SB431542 (Tocris) and 2 µM Dorsomorphin (Tocris) 
for the first day, with the addition of 200 ng ml − 1 SHH C24II (R&D Systems) and 
50 ng ml − 1 Wnt1 (Peprotech) for the second day onwards. Dkk1 blocking antibody 
(100 ng ml − 1, R&D Systems) was also added for the second day only. After 5 days, 
KSR medium containing these ligands was cross-tapered with N2B27 medium 
(Stem Cells) containing the same ligands over 7 days (75% KSR and 25% N2B27 
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Figure 5 | Gene expression profiling finds that the triplication genes are significantly enriched in AST iPSC-derived neurons. Principle components 
analysis (a) and hierarchical clustering (b) shows that iPsCs cluster with hEsCs, while fibroblasts and neurons cluster separately. There is no clear 
separation between AsT and nAs-derived cells at this level of analysis. (c) scatter plots demonstrate that global gene expression of iPsCs is more similar 
to hEsCs than fibroblasts and there are no significant differences in global gene expression between AsT and nAs iPsCs. (d) multiple views of a three-
dimensional PCA plot, following batch effect removal, comparing iPsC gene expression to all hEsC data sets on the Affymetrix u133 Plus 2.0 platform  
that are publicly available (59 samples from 8 separate submissions). The iPsCs intermingle within the hEsC landscape in all three dimensions.  
(e) Gene set enrichment analysis for the triplication genes shows significant enrichment in AsT iPsCs (nominal P-value  < 0.05) and neurons (nominal  
P-value  < 0.0001) but not fibroblasts (nominal P-value = 0.09). Enrichment score P-values are estimated by using an empirical gene set-based 
permutation test procedure40. (f) SNCA expression is higher in AsT-derived iPsCs and neurons than in equivalent cells from nAs.ARTICLE
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first day, 50% of each third day, and 25% KSR with 75% N2B27 fifth day). Once 
established in N2B27 conditions, Wnt1, Noggin, SB431542 and Dorsomorphin 
were withdrawn whereas SHH was maintained, and 20 ng ml − 1 BDNF (Peprotech), 
0.2 mM ascorbic acid (Sigma) and 100 ng ml − 1 FGF8 (Peprotech) were added. 
Three days later, cells were dissociated with Hank’s buffered saline solution for 1 h 
at room temperature, and lifted mechanically, then replated en bloc on to poly-l-
ornithine/laminin-coated plasticware. Neuronal maturation ensued with BDNF 
and ascorbic acid as before, supplemented with 10 ng ml − 1 GDNF (Peprotech), 
1 ng ml − 1 TGFβ3 (Peprotech) and 0.5 mM dibutyryl-cAMP (Merck) for the next 7 
days. After a total of 23–31 days, the resulting neuronal cultures were analysed by 
immunocytochemistry, qPCR and western blot.
Protein analysis. Fibroblast cells, neuronal cells differentiated from AST and NAS 
iPSCs and control SH-SY5Y cells were collected in radio immunoprecipitation 
buffer (Cell Signaling Technologies) and protein concentrations estimated by BCA 
assay (Thermo Scientific). Samples were diluted to equivalent protein concentration 
and then 20 µg denatured by the addition of 4× sample buffer (Invitrogen) supple-
mented with β-mercaptoethanol and boiled at 100°C for 10 min, loaded onto 12% 
Bis Tris Acrylamide gels (Invitrogen) and proteins separated by SDS–PAGE. Fol-
lowing transfer to cellulose or PVDF membrane, blots were probed for α-synuclein  
(BD Transduction#610787) and β-actin (Sigma-Aldrich #A1978) then imaged  
using either ECL (Pierce) and Kodak film, or the Odyssey imaging system (LiCor 
Biosciences). To quantify α-synuclein release by neurons, 48 h conditioned medium 
from 1 well of a 6-well plate was concentrated with Amicon Ultra-15 Centrifugal 
Filter Unit (Millipore). Released α-synuclein was assessed using an α-synuclein 
ELISA kit (USCN Life catalogue #E91222Hu) as per manufacturer’s protocol.
SNP microarray. DNA was extracted from fibroblasts, iPSCs and neuralized iPSC 
lines using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufac-
turer’s instructions. DNA was quantified spectroscopically (NanoDrop, Thermo 
Scientific) and 4 µl of 50 ng µl − 1 genomic DNA and whole-genome amplified DNA 
samples were marked on the Illumina Infinium Omni1-Quad BeadChip (Illumina) 
according to the manufacturer′s instructions. The BeadChips were scanned using 
an iScan (Illumina) with an AutoLoader (Illumina). GenomeStudio v.1.8.X (Il-
lumina) was used for analysing the data and generating SNP calls. SNP calls were 
created using the HumanOmni1-Quad_v1-0_B cluster file provided by Illumina 
as a reference. Pi-hat analysis was performed with PLINK v1.07 (http://pngu.mgh.
harvard.edu/purcell/plink/)60. All SNP data was deposited in the GEO database 
under accession code GSE28366.
Gene expression microarray. Total RNA was extracted from fibroblasts, iPSCs 
and neuralized iPSC lines using the RNeasy Plus kit (Qiagen), according to the 
manufacturer’s instructions. Following the evaluation of RNA quality by capillary 
electrophoresis (Agilent 2100 Bioanalyzer and RNA 6000 Nano Kit, Agilent) 200 ng 
of total RNA was used as starting material for the cDNA preparation. All steps 
starting from the first and second strand cDNA synthesis, the in vitro transcrip-
tion reaction to generate cRNA and the second round of cDNA synthesis were 
performed using the AmbionWT Expression Kit (Ambion), according to the 
manufacturer’s instructions. Samples were subsequently processed using the  
Affymetrix GeneChip whole transcript sense target labelling assay and hybridized 
to the Affymetrix Exon 1.0 ST or U133 Plus 2.0 Arrays following the recommended 
Affymetrix protocols. Hybridized arrays were scanned on GeneChip Scanner 3000 
and visually inspected for hybridization artefacts. The data was deposited in the 
GEO database under accession numbers GSE28365 and GSE30792.
Analysis of microarray data. Exon Array data generated from fibroblast lines 
(n = 2), iPSC lines (n = 4) and neuralized iPSC lines (n = 8) were evaluated for 
uniform hybridization intensity, abnormal background signals and sample outliers 
using Affymetrix Expression Console (Affymetrix). All arrays were preprocessed 
using RMA quantile normalization with GC background correction in Partek’s 
Genomics Suite v6.5 (Partek). Only probe sets containing a minimum of 3 probes, 
unique hybridization and designed against genes annotated within Entrez Gene 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene) as documented in the 
most recent Netaffx annotation file (HuEx-1_0-st-v2 Probeset Annotations, CSV 
Format, Release 31) were included in the analysis. Gene level summary signals 
were generated by calculating the median expression value of all probe sets an-
notated to a single gene. PCA, unsupervised hierarchical clustering, t-testing and 
gene expression scatterplot analyses were performed in Partek Genomics Suite v6.5 
(Partek). GSEA was performed using GSEA v2.0.6 (Broad Institute) using gene 
set permutation and a triplication gene set, which was defined as all genes present 
within the triplication region (as identified on SNP array assessment)40. Follow-
ing removal of batch effects, iPSC data analysed using Affymetrix U133 Plus 2.0 
Arrays were compared via principal components analysis with the following data 
sets, all publicly available via the GEO database under accession codes: GSE16190, 
GSE19902, GSE22499, GSE26451, GSE7179, GSE7879, GSE8590 and GSE9440. 
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